← Back to Clinical Trials
Recruiting NCT05546086

BeijngFH Health Cohort Study

Trial Parameters

Condition Non-Alcoholic Fatty Liver Disease
Sponsor Beijing Friendship Hospital
Study Type OBSERVATIONAL
Phase N/A
Enrollment 8,103
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2022-04-18
Completion 2032-04-18

Brief Summary

Metabolic associated fatty liver disease(MEFLD) is a major chronic liver disease that can lead to various adverse events, such as liver cancer, cardiovascular disease, and chronic kidney disease. The present community-based cohort study enrolls subjects who take health physical examinations at the sub-center outpatient department, Beijing Friendship Hospital. Investigators collect their baseline information, including demographic data, clinical history, physical examination, laboratory results, imageological examination, and so on. Follow-up surveys are conducted annually and the information collected is the same as the baseline. The outcome information, including cardiovascular disease, malignancy, liver cirrhosis, liver decompensation, liver transplantation, and all-cause mortality, are obtained by linking to the hospital discharge database and death registration system of Beijing. The primary aim of the study is to build a risk-stratified evaluation system for MAFLD through the cohort.

Eligibility Criteria

Inclusion Criteria: * Aged 18 years or older * Permanent residents in Beijing * Signing informed consent Exclusion Criteria: * No

Related Trials